Skip to main content

Table 3 Comparison of characteristics of patients with uveitis

From: Epidemiology of pediatric uveitis and associated systemic diseases

Characteristics

(1) Uveitis with Systemic immune-mediated disease, n = 44

(2) JIA-related uveitis, n = 23

(3) Idiopathic uveitis, n = 101

p-value

[(1) vs. (3)]

p-value

[(2) vs. (3)]

Sex, N(%)

 Male

25 (56.8)

15 (65.2)

48 (47.5)

0.303

0.126

 Female

19 (43.2)

8 (34.8)

53 (52.5)

  

Median age at uveitis diagnosis, y (IQR)

13.0 (10.0–16.0)

11.0 (6.5–16.0)

13.0 (10.0–16.0)

0.914

0.251

Laboratory findings

 HLA-B27 tested, N

27

16

43

  

 Positive, N (%)

8 (29.6)

7 (43.8)

5 (11.6)

0.059

0.006

 HLA-B51 tested, N

18

5

41

  

 Positive, N (%)

5 (27.8)

1 (20.0)

7 (17.1)

0.347

0.871

 RF tested, N

41

23

71

  

 Positive, N (%)

5 (12.2)

3 (13.0)

5 (7.0)

0.357

0.370

 ANA tested, N

40

23

66

  

 Positive, N (%)

16 (40.0)

13 (56.5)

17 (25.8)

0.125

0.007

Type, N (%)

 Unilateral

18 (40.9)

15 (65.2)

54 (53.5)

0.164

0.306

 Bilateral

26 (59.1)

8 (34.8)

47 (46.5)

  

Location, N (%)

 Anterior

22 (50.0)

13 (56.5)

52 (51.5)

0.633

0.779

 Intermediate

1 (2.3)

1 (4.4)

9 (8.9)

  

 Posterior

1 (2.3)

0 (0.0)

2 (2.0)

  

 Panuveitis

14 (31.8)

5 (21.7)

25 (24.8)

  

 Unknown

6 (13.6)

4 (17.4)

13 (12.9)

  

Treatment, N (%)

 Topical steroid

44 (100.0)

23 (100.0)

101 (100.0)

  

 Systemic steroid

37 (84.1)

20 (87.0)

35 (34.6)

< 0.001

< 0.001

 Synthetic DMARDs

31 (70.5)

17 (73.9)

15 (14.9)

< 0.001

< 0.001

 Biological DMARDs

11 (25.0)

6 (26.1)

0 (0.0)

< 0.001

< 0.001

Ocular complications, N (%)

21 (47.7)

11 (47.8)

35 (34.7)

0.137

0.238

  1. y years, JIA juvenile idiopathic arthritis, IQR interquartile range, HLA human leukocyte antigen, RF rheumatoid factor, ANA antinuclear antibody, DMARDs disease-modifying antirheumatic drugs